Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)335.95
  • Today's Change3.03 / 0.91%
  • Shares traded1.63m
  • 1 Year change+27.10%
  • Beta0.6055
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments10,9449,3058,037
Total Receivables, Net7,9426,3925,839
Total Inventory9,5184,9304,086
Prepaid expenses1,6471,2041,223
Other current assets, total281355200
Total current assets30,33222,18619,385
Property, plant & equipment, net6,5926,0065,750
Goodwill, net18,62915,52914,890
Intangibles, net32,64116,08015,182
Long term investments251249573
Note receivable - long term------
Other long term assets8,7095,0715,385
Total assets97,15465,12161,165
LIABILITIES
Accounts payable1,5901,5721,366
Accrued expenses12,49010,1928,947
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,4431,59187
Other current liabilities, total2,8692,3321,784
Total current liabilities18,39215,68712,184
Total long term debt63,17037,35433,222
Total debt64,61338,94533,309
Deferred income tax2,354----
Minority interest------
Other liabilities, total7,0068,4199,059
Total liabilities90,92261,46054,465
SHAREHOLDERS EQUITY
Common stock33,07032,51432,096
Additional paid-in capital------
Retained earnings (accumulated deficit)(26549)(28622)(24600)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(289)(231)(796)
Total equity6,2323,6616,700
Total liabilities & shareholders' equity97,15465,12161,165
Total common shares outstanding535534558
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.